Erratum: Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: An analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial (Journal of the American College of Cardiology (2005) 45 (1932-1938) PII: S0735-1097(05)00672-8 and DOI: 10.1016/j.jacc.2005.02.074);Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: An analysis from the Randomized Evaluation In Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial

Journal of the American College of Cardiology

Volumn 45, Issue 12, 2005, Pages 1932-1938

  Gurm, Hitinder S ^a   Sarembock, Ian J ^b   Kereiakes, Dean J ^c   Young, John J ^d   Harrington, Robert A ^e   Kleiman, Neal ^e   Feit, Frederick ^f   Wolski, Kathy ^a   Bittl, John A ^g   Wilcox, Robert ^h   Topol, Eric J ^a   Lincoff, A Michael ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c The Carl & Edyth Lindner Center for Research & Education   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Munroe Regional Med Center   (United States)

^h NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 20444503437     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.06.018     Document Type: Erratum

References (24)

1. G.G. Biondi-Zoccai, A. Abbate, G. Liuzzo, L.M. Biasucci Atherothrombosis, inflammation, and diabetes J Am Coll Cardiol 41 2003 1071 1077
2. M. Roffi, D.P. Chew, D. Mukherjee Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes Circulation 104 2001 2767 2771
3. D.L. Bhatt, S.P. Marso, A.M. Lincoff, K.E. Wolski, S.G. Ellis, E.J. Topol Abciximab reduces mortality in diabetics following percutaneous coronary intervention J Am Coll Cardiol 35 2000 922 928
4. A.M. Lincoff, J.A. Bittl, R.A. Harrington Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention REPLACE-2 randomized trial JAMA 289 2003 853 863
5. H.S. Gurm, A.M. Lincoff, D. Lee Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition lessons from the GUSTO V trial J Am Coll Cardiol 43 2004 542 548
6. D.M. Lloyd-Jones, C.A. Camargo, L.A. Allen, R.P. Giugliano, C.J. O'Donnell Predictors of long-term mortality after hospitalization for primary unstable angina pectoris and non-ST-elevation myocardial infarction Am J Cardiol 92 2003 1155 1159
7. K. Malmberg, S. Yusuf, H.C. Gerstein Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry Circulation 102 2000 1014 1019
8. C.G. Koch, Y.S. Weng, S.X. Zhou Prevalence of risk factors, and not gender per se, determines short- and long-term survival after coronary artery bypass surgery J Cardiothorac Vasc Anesth 17 2003 585 593
9. J.J. Morris, L.R. Smith, R.H. Jones Influence of diabetes and mammary artery grafting on survival after coronary bypass Circulation III84 1991 275 284
10. G.W. Barsness, E.D. Peterson, E.M. Ohman Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty Circulation 96 1997 2551 2556
11. R. Mehran, G.D. Dangas, Y. Kobayashi Short- and long-term results after multivessel stenting in diabetic patients J Am Coll Cardiol 43 2004 1348 1354
12. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease N Engl J Med 335 1996 217 225
13. K.M. Detre, P. Guo, R. Holubkov Coronary revascularization in diabetic patients a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI) Circulation 99 1999 633 640
14. W.K. Laskey, F. Selzer, H.A. Vlachos Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry) Am J Cardiol 90 2002 1062 1067
15. V. Mathew, B.J. Gersh, B.A. Williams Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial Circulation 109 2004 476 480
16. S.P. Marso, A.M. Lincoff, S.G. Ellis Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy Circulation 100 1999 2477 2484
17. The ERASER Investigators Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study) Circulation 100 1999 799 806
18. A.J. Chaves, A.G. Sousa, L.A. Mattos Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab results of the Diabetes Abciximab steNT Evaluation (DANTE) randomized trial Circulation 109 2004 861 866
19. A.M. Lincoff Important triad in cardiovascular medicine diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade Circulation 107 2003 1556 1559
20. M. Roffi, E.J. Topol Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes Eur Heart J 25 2004 190 198
21. J. Mehilli, A. Kastrati, H. Schuhlen Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel Circulation 110 2004 3627 3635
22. W.H. Tang, A.M. Lincoff Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa blockade the triad revisited Circulation 110 2004 3618 3620
23. M. Roffi, D.J. Moliterno, B. Meier Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up Circulation 105 2002 2730 2736
24. E.J. Topol, A.M. Lincoff, D.J. Kereiakes Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization Am J Med 113 2002 1 6